Core Viewpoint - Regeneron Pharmaceuticals has faced challenges in the past year, particularly with its Eylea product, leading to a 30% decline in stock price, but there are strong reasons to consider it a long-term investment opportunity [1] Group 1: Eylea's Performance - Eylea, a treatment for wet age-related macular degeneration, has seen slowed sales growth due to increased competition, including a biosimilar from Amgen, resulting in only a 2% year-over-year sales increase to 1.5billioninthefourthquarter[2][3]−ThedeclineinEylea′sperformancehasraisedconcernsamonginvestors,buttheoverallrevenueforRegenerongrewby103.8 billion, largely driven by Dupixent [3] Group 2: Dupixent's Growth - Dupixent, co-marketed with Sanofi, experienced a 15% year-over-year sales increase to 3.7billion,makingitoneofthetop−sellingdrugsglobally[4]−RegeneronandSanofiarepursuinglabelexpansionsforDupixent,includinganewindicationfortreatingbullouspemphigoid,whichcouldfurtherboostsales[5]Group3:InnovativePipeline−Regeneronisdevelopingapromisinggenetherapyforcongenitaldeafness,showingpositiveresultsinearly−stagetrials,with10outof11patientsexperiencingimprovedhearing[6][7]−TheongoingdevelopmentofinnovativetreatmentspositionsRegeneronwellforfuturegrowthbeyondEyleaandDupixent[8]Group4:CapitalReturntoShareholders−Regeneronhasannouncedaquarterlydividendof0.88 and is actively engaging in a stock buyback program, indicating a commitment to returning capital to shareholders [9] - The company's strong operational performance supports the sustainability of its dividend program [9] Group 5: Overall Investment Appeal - Regeneron's ability to innovate, robust operational performance, and prudent capital allocation make it an attractive investment option despite recent stock price declines [10]
Regeneron(REGN) The Motley Fool·2025-03-09 10:20